INTRODUCTION AND OBJECTIVES:
Since the reclassification of transvaginal mesh as a high-risk device, there is renewed interest in non-mesh pelvic organ prolapse (POP) repair. Our goal was to develop a transvaginal repair for anterior and apical vaginal prolapse with the use of only autologous fascia lata graft. We report our experience in our first 33 patients.
METHODS: Autologous Anterior and Apical Pelvic Organ Prolapse (AAA-POP) repair utilizes a 4 cm x 14 cm piece of fascia lata harvested through a single 3-4 inch lateral upper thigh incision. The graft is cut into 3 strips approximately 1.3 cm x 14 cm which are reconfigured to provide apical fixation to the sacrospinous ligaments and distal fixation to the obturator fascia at the level of the bladder neck. Patients were followed by history, SEAPI scores, POP-Q scores, and symptoms related to thigh harvest including visual analog pain (VAP) scores. Treatment failure was defined as symptomatic anterior and/or apical POP.
RESULTS: The AAA-POP procedure was performed on 33 patients with a mean age of 62. Mean follow-up was 8 months (range 1-25 months), with 10 patients having 12 or more months of followup. 13 patients had prior vaginal mesh removal. POP symptoms resolved in 32 patients, and there was one treatment failure (Stage II uterine POP). Ten patients developed post-operative retention, 9 of whom had undergone concurrent pubovaginal sling. Four of the retention patients required urethral dilation, and five underwent sling lysis. The overwhelming majority of harvest site issues were minor and managed expectantly. Mean VAP score at the harvest site was 0.24. Five patients developed non-bothersome thigh bulges, all of which were managed expectantly. Harvest site seroma occurred in 4 patients and all resolved with 2 requiring simple aspiration. Eight patients reported mild, non-bothersome harvest site paresthesia. No thromboembolic events occurred.
CONCLUSIONS: AAA-POP repair is an efficacious treatment for the mesh-injured and other patients who desire non-mesh POP repair. Patients should be counseled regarding harvest site issues, which typically resolve with expectant management alone. Patients undergoing concurrent pubovaginal sling should be counseled regarding the risk of urinary retention. Continued follow-up of this series is ongoing to determine long-term success of AAA-POP repair.
Source of Funding: None

MP02-12 A MULTICENTER RANDOMIZED TRIAL COMPARING ROBOT-ASSISTED VERSUS PURE LAPAROSCOPIC SACROCOLPOPEXY FOR PELVIC ORGAN PROLAPSE.
Laurent Wagner, Nîmes, France; Serge Douvier, Dijon, France; Alain Ruffion, Lyon, France; Christian Saussine, Strasbourg, France; Laurent Soustelle, Nîmes, France; Jerome Rigaud, Guillaume Meurette, Nantes, France; Emmanuel Chartier-Kastler, Paris, France; Adrien Vidart, Surrenes, France; Andrea Manunta, Rennes, France; Etienne Vincens, Paris, France; Maxence Dorez, Nice, France; M elanie Cayrac, Montpellier, France; Jean-Luc Hoepffner, Bordeaux, France; Pierre Costa, Nimes, France; St ephane Droupy*, Nîmes, France INTRODUCTION AND OBJECTIVES: Pelvic organ prolapse (POP) is a frequent and invalidating condition in women, and surgery is an option for women with troublesome prolapse. The challenge in prolapse repair surgery is to restore women well-being, self-image, and quality of life without inducing adverse effects or sequelae. A woman's lifetime risk of undergoing surgery for pelvic organ prolapse surgery by the age of 80 is around 19%. Laparoscopic sacrocolpopexy (LS) with synthetic non-absorbable mesh is considered the gold standard. Since the introduction of robotic-assisted sacrocolpopexy (RAS) in 2006, this approach has gain interest and 21000 procedures have been undergone in 2017 worldwide.
Retrospective and under-powered prospective comparative studies indicated that robotic-assistance is associated with a reduced risk of complications, shorter hospital stay and a shorter learning curve but increased costs as compared with LS.
METHODS: We report the results of a multicenter, randomized, controlled trial (clinicalTrials.gov number, NCT 01320215) designed to assess whether RAS would be associated with a lower rate of perioperative complications than pure LS. Patient with a first (primo-event), symptomatic, genitourinary prolapse of at least stage II (POP-Q classification) requiring surgery, were recruited in 16 centers from July 2011 to October 2016. All the surgeons participating in the study were experienced in pure LS (at least 20 cases) and RAS (at least 10 cases). The primary objective was to compare 30-day complication rates and secondary objectives included comparing technical data, anatomical correction, recurrence, incontinence, quality of life and medicoeconomic data between arms, during 5 years follow up. Complications were defined as at least one of the following surgical complications (bleeding complications: hemoperitoneum, blood loss ! 500 ml, transfusion; any wound caused by a surgeon movement: bladder, digestive, ureteral, or vascular injuries; trocart sites: infection, hernia; conversion to a laparoscopic or open surgical technique not related to pre-existing adhesions; reintervention) or medical complications (deep vein thrombosis, pulmonary embolism, pneumopathy, urinary tract infection; chronic pain) RESULTS: Overall, 345 patients were randomly assigned to both arms (170 RAS, 175 LS). On the basis of an intent to treat analysis, we found that 20 patients (11,76%) in the RAS group and 27 patients in the LS group (15,43%) had complications (P[0.3213). Surgical complications were found in 6 patients (3,5%) in the RAS and 16 (9,1%) in the LS group (P[0,04). Length of surgery, anesthesia and hospital stay were similar between groups. However, when a complication occured the mean hospital stay was 5.6 days in the LS group and 3.8 in the RAS group (P[0,01). Median experience of surgeons was 60 cases for LS and 20 cases for RAS.
CONCLUSIONS: This randomized controlled trial showed similar rates of perioperative complications and lenght of hospital stay among patients who underwent RAS or LS. However, RAS group showed less surgical complications despite less experienced surgeons suggesting that the robot provides at least similar surgical skills with a shorter learning curve.
Source of Funding: French ministry of health (PHRC national)
MP02-13 TRENDS AND SAFETY OF CONCURRENT SACROCOLPOPEXY AND RECTOPEXY
Claire S. Burton*, Catherine Bresee, Colby P. Souders, Los Angeles, CA; Alex Hannemann, Vermillion, SD; Karyn S. Eilber, Jennifer T. Anger, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Women with pelvic floor disorders may experience both vaginal and rectal prolapse, and several recent reports have proposed the use of concurrent sacrocolpopexy and rectopexy to reduce patient morbidity and improve patient outcomes. We evaluate the temporal trends of concurrent rectopexy and sacrocolpopexy and compare complication rates between individual and concurrent procedures using the National Inpatient Sample (NIS).
METHODS: The NIS, maintained by the Healthcare Cost and Utilization Project (HCUP), contains approximately 20% of all hospital admissions in the United States from a stratified sample. We identified women who underwent either sacrocolpopexy (70.77, 70.78) or rectopexy (48.75, 48.76 ) by ICD-9 procedure codes between 2010-2014.
RESULTS: There were 160,714 women who underwent sacrocolpopexy, 24,493 who underwent rectopexy, and 2,354 who had concurrent sacrocolpopexy and rectopexy during the period of 2010 -Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e15
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